title: [Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose].
abstract: OBJECTIVE
  Our study compares clinical and therapeutic courses (corticosteroid response, corticosteroid amount, complications) in people with giant cell arteritis before and over 75 years, during the first year of treatment.
  
  
  METHODS
  A series of 164 patients was retrospectively analysed (mean age: 73.3 years) among the two subgroups: before 75 and over 75 years. Patient received (monitoring of reduction in the corticosteroid dosage) a 240 mg intravenous bolus of methylprednisolone followed by 0.5 or 0.7 mg/kg/d of prednisone, or 0.7 mg/kg/d of prednisone without the bolus.
  
  
  RESULTS
  Corticosteroid response was identical for the two groups, before and over 75 (patients with corticoresistance: 15% vs 11.4%; NS) and giant cell arteritis-related complications were equivalent (n = 2 vs n = 2; NS). Corticosteroid load was slightly lower in the elderly group (cumulative dose of corticosteroids during the first year of treatment 5.2 g vs 5.8 g; P = 0.03). Patients with rheumatic side effects (collapses of vertebral bodies, mainly) were more frequent in the elderly group (15.5% vs 4.3%; P = 0.01), in spite of a limited mean follow-up period (10.7 months).
  
  
  CONCLUSIONS
  Even if steroid response was identical in the therapeutic course of giant cell arteritis, rheumatic side effects appeared more frequent in the elderly group (over 75 years). In order to obtain a corticosteroid-sparing effect, new studies are necessary to evaluate a reduced initial dosage of corticosteroids.
authors.affiliation: Service de gériatrie, Hôpital Saint-Jacques, 85, rue Saint-Jacques, 44093 Nantes, France.
authors.forename: P
authors.initials: P
authors.lastname: Chevalet
authors.forename: J H
authors.initials: JH
authors.lastname: Barrier
authors.forename: J
authors.initials: J
authors.lastname: Glémarec
authors.forename: D
authors.initials: D
authors.lastname: el Kouri
authors.forename: M
authors.initials: M
authors.lastname: Hamidou
authors.forename: B
authors.initials: B
authors.lastname: de Wazières
authors.forename: E
authors.initials: E
authors.lastname: Duhamel
authors.forename: P
authors.initials: P
authors.lastname: Jégo
authors.forename: Y
authors.initials: Y
authors.lastname: Maugars
authors.forename: B
authors.initials: B
authors.lastname: Planchon
authors.forename: O
authors.initials: O
authors.lastname: Rodat
mesh_terms: D000367:Age Factors; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001706:Biopsy; D018450:Disease Progression; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D013700:Giant Cell Arteritis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000009:adverse effects*; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone; D008775:Methylprednisolone
vernacular_title: Maladie de Horton du sujet âgé de plus de 75 ans: particularites évolutives, complications de la corticothérapie. Etude comparative sur une série de 164 patients. Vers une dose d'attaque réduite.